NCT04417192 (OLAPem) is a Phase 2 clinical trial of Olaparib in Ovarian Cancer, sponsored by National Cancer Center Hospital East.

Who is sponsoring NCT04417192?

NCT04417192 is sponsored by National Cancer Center Hospital East.

What drugs are being tested in NCT04417192?

Interventions in NCT04417192: Olaparib, Pembrolizumab.

What condition does NCT04417192 study?

NCT04417192 studies Ovarian Cancer.

Is NCT04417192 still recruiting?

NCT04417192 is currently completed. Last updated 6 July 2023.

Last reviewed 2023-07-06 · How we verify

NCT04417192: OLAPem

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

Completed Phase 2 Last updated 6 July 2023

What this trial tests

Phase 2 trial testing Olaparib in Ovarian Cancer in 30 participants. Completed in 30 June 2023.

Timeline

1 December 2020

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	National Cancer Center Hospital East
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 December 2020
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	3 locations across Japan

Drugs / interventions tested

Olaparib (olaparib) — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

National Cancer Center Hospital East

Who can join

20 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of preoperative olaparib monotherapy and preoperative olaparib plus pembrolizumab combination therapy in patients with untreated stage III, IV high-grade serous or Grade 3 endometrioid ovarian cancer with Homologous Recombination Deficiency (HRD) positivity.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C, Qin K, Lin A, Jiang A, et al · · 2022 · cited 60× · PMID 36071479 · DOI 10.1186/s13046-022-02469-0
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. · · 2021 · cited 60× · PMID 34503248 · DOI 10.3390/cancers13174438
Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
Pawłowska A, Rekowska A, Kuryło W, Pańczyszyn A, et al · · 2023 · cited 41× · PMID 37446039 · DOI 10.3390/ijms241310859
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
Musacchio L, Cicala CM, Camarda F, Ghizzoni V, et al · · 2022 · cited 37× · PMID 35849879 · DOI 10.1016/j.esmoop.2022.100536
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, et al · · 2022 · cited 28× · PMID 35409229 · DOI 10.3390/ijms23073871
Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.
Hu X, Bian C, Zhao X, Yi T. · · 2022 · cited 19× · PMID 36275669 · DOI 10.3389/fimmu.2022.1034903
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer.
Xiao F, Wang Z, Qiao L, Zhang X, et al · · 2024 · cited 18× · PMID 39169400 · DOI 10.1186/s12967-024-05583-z
Towards Personalized Management of Ovarian Cancer.
Algethami M, Kulkarni S, Sadiq MT, Tang HKC, et al · · 2022 · cited 10× · PMID 36545222 · DOI 10.2147/cmar.s366681

Verify or expand the search:

Other trials of Olaparib

Trials testing the same drug.

NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other National Cancer Center Hospital East trials

Trials by the same sponsor.

NCT07100704 — Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab · Phase 2 · recruiting
NCT07529613 — Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junct · Phase 1, PHASE2 · completed
NCT05646511 — TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT05394740 — Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy · Phase 1, PHASE2 · completed
NCT05034887 — Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus D · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04417192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Center Hospital East
Last refreshed: 6 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04417192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing